ProGnosis Biotech
Private Company
Total funding raised: $2.1M
Overview
ProGnosis Biotech is an EU-based diagnostics company founded in 2015, developing and manufacturing ELISA and Lateral Flow Tests for food safety, clinical diagnostics, and hygiene monitoring. The company leverages its antigen-antibody technology platform to deliver rapid, reliable, and eco-friendly testing solutions validated by international bodies. With ISO-certified production and a growing portfolio, ProGnosis serves global markets while expanding into new areas like cardiac markers and contract manufacturing services.
Technology Platform
Immunoassay platform specializing in the development and manufacturing of ELISA (Enzyme-Linked Immunosorbent Assay) and Lateral Flow Assays (LFAs) with a focus on eco-friendly innovations like non-organic solvent extractions.
Funding History
1Opportunities
Risk Factors
Competitive Landscape
ProGnosis competes in fragmented but competitive markets against large multinational life science tools companies (e.g., Thermo Fisher, Merck) and specialized diagnostics firms (e.g., R-Biopharm, Hygiena). Its differentiation lies in its EU-based manufacturing, eco-innovative processes, multi-sector focus, and validation by recognized international bodies.